IPP Bureau

Oncodesign Services and Veritas In Silico jointly to develop mRNA-targeted small molecule drugs
Oncodesign Services and Veritas In Silico jointly to develop mRNA-targeted small molecule drugs

By IPP Bureau - May 25, 2023

The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets

Tata 1mg-backed 5C Network launches diagnostics-on-demand platform Prodigi PASS
Tata 1mg-backed 5C Network launches diagnostics-on-demand platform Prodigi PASS

By IPP Bureau - May 24, 2023

5C Network’s groundbreaking platform aims to bring together diagnostic facilities and healthcare aggregators on a single platform to deliver an unparalleled patient experience

Lonza launches TheraPEAK T-VIVO cell culture medium to accelerate cell therapy development
Lonza launches TheraPEAK T-VIVO cell culture medium to accelerate cell therapy development

By IPP Bureau - May 24, 2023

Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing

Neutec introduces the oCelloscope automated microbial live-cell imaging technology
Neutec introduces the oCelloscope automated microbial live-cell imaging technology

By IPP Bureau - May 24, 2023

The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development

Venus Remedies gets Kenyan GMP certification for its manufacturing facilities in Baddi
Venus Remedies gets Kenyan GMP certification for its manufacturing facilities in Baddi

By IPP Bureau - May 24, 2023

The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans

Biocon posts Q4 FY23 consolidated PAT at Rs. 313.2 Cr
Biocon posts Q4 FY23 consolidated PAT at Rs. 313.2 Cr

By IPP Bureau - May 24, 2023

The company has reported total income of Rs. 3928.8 crores during the period ended March 31, 2023

Shilpa Medicare Analytical Services Division gets VAI status from USFDA after GMP inspection
Shilpa Medicare Analytical Services Division gets VAI status from USFDA after GMP inspection

By IPP Bureau - May 23, 2023

This is the second US FDA GMP inspection of this facility within one year

Sun Pharma Advanced Research Company posts Q4 FY23 loss at Rs. 81.99 Cr
Sun Pharma Advanced Research Company posts Q4 FY23 loss at Rs. 81.99 Cr

By IPP Bureau - May 23, 2023

The company has reported total income of Rs. 58.42 crores during the period ended March 31, 2023

Agilent to appeal patent office decision on CRISPR gRNA patents
Agilent to appeal patent office decision on CRISPR gRNA patents

By IPP Bureau - May 23, 2023

Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination

Freenome acquires global immunodiagnostics developer Oncimmune
Freenome acquires global immunodiagnostics developer Oncimmune

By IPP Bureau - May 23, 2023

Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection

Roche introduces navify sample tracking for labs to track patient test samples
Roche introduces navify sample tracking for labs to track patient test samples

By IPP Bureau - May 23, 2023

navify Sample Tracking is part of the navify Diagnostics portfolio, a set of digital solutions enabling labs to drive end-to-end operational excellence across care settings.

Anuh Pharma posts Q4 FY23 PAT at Rs. 9.62 Cr
Anuh Pharma posts Q4 FY23 PAT at Rs. 9.62 Cr

By IPP Bureau - May 22, 2023

Anuh Pharma has reported total income of Rs. 158.34 crores during the period ended March 31, 2023

Zydus receives final approval from the USFDA for Ephedrine Sulfate Injection
Zydus receives final approval from the USFDA for Ephedrine Sulfate Injection

By IPP Bureau - May 22, 2023

Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States

Eris Lifesciences posts consolidated Q4FY23 PAT at Rs. 65.41 Cr
Eris Lifesciences posts consolidated Q4FY23 PAT at Rs. 65.41 Cr

By IPP Bureau - May 22, 2023

Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023

Zydus Wellness' FY23 consolidated net sales up 12.8% at Rs. 2243 Cr
Zydus Wellness' FY23 consolidated net sales up 12.8% at Rs. 2243 Cr

By IPP Bureau - May 22, 2023

Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in their respective categories as on March 2023

Latest Stories

Interviews

Packaging